Neuronal Calcium Sensor 1 is up-regulated in response to stress to promote cell survival and motility in cancer cells

Henrike K. Grosshans¹,*, Tom T. Fischer¹,² †, Julia A. Steinle¹, Julius L. Brill³ † and Barbara E. Ehrlich¹,³ †

¹ Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA
² Institute of Pharmacology, Heidelberg University, Germany
³ Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA

Keywords
Ca²⁺ binding protein; Ca²⁺ signaling; NFκB; PKB/Akt; tumor progression

Correspondence
B. E. Ehrlich, Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8066, USA
Tel: +1 203-737-1158
E-mail: barbara.ehrlich@yale.edu

Present address
*University of Freiburg School of Medicine, Germany
†University of Muenster School of Medicine, Germany

(Received 10 September 2019, revised 8 February 2020, accepted 25 March 2020, available online 28 April 2020)
doi:10.1002/1878-0261.12678

Changes in intracellular calcium (Ca²⁺) signaling can modulate cellular machinery required for cancer progression. Neuronal calcium sensor 1 (NCS1) is a ubiquitously expressed Ca²⁺-binding protein that promotes tumor aggressiveness by enhancing cell survival and metastasis. However, the underlying mechanism by which NCS1 contributes to increased tumor aggressiveness has yet to be identified. In this study, we aimed to determine (a) whether NCS1 expression changes in response to external stimuli, (b) the importance of NCS1 for cell survival and migration, and (c) the cellular mechanism(s) through which NCS1 modulates these outcomes. We found that NCS1 abundance increases under conditions of stress, most prominently after stimulation with the pro-inflammatory cytokine tumor necrosis factor α, in a manner dependent on nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). We found that NFκB signaling is activated in human breast cancer tissue, which was accompanied by an increase in NCS1 mRNA expression. Further exploration into the relevance of NCS1 in breast cancer progression showed that knockout of NCS1 (NCS1 KO) caused decreased cell survival and motility, increased baseline intracellular Ca²⁺ levels, and decreased inositol 1,4,5-trisphosphate-mediated Ca²⁺ responses. Protein kinase B (Akt) activity was decreased in NCS1 KO cells, which could be rescued by buffering intracellular Ca²⁺. Conversely, Akt activity was increased in cells overexpressing NCS1 (NCS1 OE). We therefore conclude that NCS1 acts as cellular stress response protein up-regulated by stress-induced NFκB signaling and that NCS1 influences cell survival and motility through effects on Ca²⁺ signaling and Akt pathway activation.

1. Introduction

Disrupted intracellular calcium (Ca²⁺) signaling leads to a variety of pathological conditions (Carafoli, 2002; Clapham, 2007), including tumor development and progression (Monteith et al., 2017). Under resting conditions, free cytoplasmic Ca²⁺ levels are kept at low concentrations (100 nM), such that following defined stimuli, Ca²⁺ levels can be raised and used as an effective second messenger. Ca²⁺ transients cause a broad

Abbreviations
Akt, protein kinase B; Ca²⁺, calcium; ER, endoplasmic reticulum; InsP3, inositol 1,4,5-trisphosphate; InsP3R, inositol 1,4,5-trisphosphate receptor; IκBα, nuclear factor of kappa-light polypeptide gene enhancer in B-cell inhibition, alpha; NCS1, neuronal calcium sensor 1; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; p-Akt, phosphorylated Akt; PI3K, phosphoinositide-3-kinase; PP2Ac, catalytic subunit of protein phosphatase 2A; tBHP, tert-butylhydroperoxide; TG, thapsigargin; TNF-α, tumor necrosis factor alpha.
variety of outcomes not only due to the tightly regulated spatial and temporal occurrence of Ca^{2+} signals, but also due to the existence of Ca^{2+}-binding proteins. Upon binding of Ca^{2+}, these proteins can change conformation and interact with other effector proteins. As such, Ca^{2+}-binding proteins are essential for regulation of cellular homeostasis.

Changes in the expression levels or functionality of Ca^{2+}-binding proteins can lead to numerous diseases, including cancer. A well-established example of this is the S100 family of Ca^{2+}-binding proteins, which promote tumor aggressiveness in several different cancer types, such as breast, lung, prostate, colorectal, and liver cancers (Bresnick et al., 2015). Interestingly, S100A7 is not expressed in healthy breast tissue, but is highly expressed in multiple types of breast cancer and activates several pro-survival pathways, including those that rely upon signaling of nuclear factor kappalight-chain-enhancer of activated B cells (NFκB) and protein kinase B (Akt) (Bresnick et al., 2015; Salama et al., 2008). The expression of another member of the S100 family, S100A6, is induced by tumor necrosis factor α (TNF-α), a strong activator of NFκB (Joo et al., 2003), and promotes cell proliferation and migration through activation of the Akt pathway (Li et al., 2014). These findings provide insights into how Ca^{2+}-binding proteins can affect tumor progression. Here, we focus on the Ca^{2+}-binding protein neuronal calcium sensor 1 (NCS1), which shares multiple characteristics with the S100 protein family. Like S100 proteins, NCS1 belongs to the EF-hand superfamily of Ca^{2+}-binding proteins (Burgoyne, 2007; Donato et al., 2013), is increased in cancerous tissues, and contributes to a more aggressive phenotype of these tumors (Apasu et al., 2019; Moore et al., 2017; Moore et al., 2018; Schuette et al., 2018). It binds Ca^{2+} with high affinity and contains four EF-hand domains, three of which bind Ca^{2+}, and one of which, in the N-terminal domain, is unable to bind Ca^{2+} (Boeckel and Ehrlich, 2018; Bourne et al., 2001).

NCS1 was first thought to be expressed only in neuronal cells, but is now known to be expressed and to have essential functions in almost every tissue type (Burgoyne, 2007). Besides its ability to bind and buffer intracellular Ca^{2+}, NCS1 can modulate numerous effector proteins, including the inositol 1,4,5-trisphosphate receptor (InsP3R) (Schlecker et al., 2006), phosphatidylinositol-4-kinase IIβ (Graham and Burd, 2011), and calcineurin (Schaad et al., 1996). These interactions, the capacity to bind and buffer Ca^{2+}, and its broad tissue distribution help to explain its diverse set of functions. For example, in neurons NCS1 is involved in Ca^{2+} signal transduction (Dragicevic et al., 2014; Weiss et al., 2010), exocytosis (Koizumi et al., 2002), membrane trafficking (Zhao et al., 2001), cell survival (Nakamura et al., 2006), and hippocampal learning (Sippy et al., 2003). In the heart, NCS1 plays an essential role in development and function, as it regulates cardiomyocyte contraction and contributes to the stress tolerance of cardiac cells (Nakamura et al., 2011; Nakamura et al., 2016; Nakamura-Nishitani and Wakabayashi, 2014). NCS1 is also involved in the development and progression of breast and liver cancer (Apasu et al., 2019; Moore et al., 2017; Moore et al., 2018; Schuette et al., 2018). Whereas NCS1 levels do not significantly differ among healthy individuals, they rise during the development of aggressive tumors, and increased levels are correlated with worse patient outcome (Moore et al., 2017; Moore et al., 2018; Schuette et al., 2018). High NCS1 levels promote tumor aggressiveness by enhancing cell survival and migration in 2D and 3D cell culture models and in mice (Apasu et al., 2019). However, the underlying cellular mechanisms for these observations are not yet determined.

In this study, we aimed to investigate the mechanisms by which NCS1 enhances tumor progression and aggressiveness. Our primary goal was to determine the specific extracellular conditions and intracellular signaling pathway(s) that lead to increased NCS1 expression in cancer cells. For this purpose, we explored whether NCS1 expression levels change in response to external stimuli in vitro and investigated the translational relevance of the identified signaling mechanism in human cancer. We determined the importance of NCS1 for cell survival and migration using a model of breast cancer cells (MDA-MB231) lacking NCS1 expression. Finally, we investigated whether cellular mechanisms are used by NCS1 to affect cell survival and migration, focusing on Ca^{2+} homeostasis, InsP3-mediated Ca^{2+} signaling, and phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) pathway (Akt pathway) activation. Overall, we describe a novel mechanism through which NCS1 functions as a stress response protein to promote cell survival and motility.

2. Methods

2.1. Cell culture

MDA-MB231 human breast cancer and SHSY5Y human neuroblastoma cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). ATCC validates all cell lines by short-tandem repeat analysis. MDA-MB231 cell lines...
were maintained at 37 °C with 5% CO₂ in Dulbecco’s modified essential medium (DMEM) supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin. MDA-MB231 cells stably overexpressing NCS1 (Moore et al., 2017) were cultured in the medium described above plus 1 mg·mL⁻¹ G418. SHSY5Y cells were maintained at 37 °C with 5% CO₂ in DMEM/F12 medium supplemented with 10% FBS, 1% nonessential amino acids, and 1% penicillin/streptomycin.

2.2. In vitro treatments

To study the effect of cellular stressors on NCS1 expression, SHSY5Y cells were treated with various stimuli. To specifically activate the transcription factor NFκB, cells were treated with 10 ng·mL⁻¹ TNF-α (Sigma-Aldrich, St. Louis, MO, USA) for 24–36 h. For NFκB inhibition, 1 µM Bay 11-7082 (Sigma-Aldrich) was used for 24 h. Bay 11-7082 was either applied alone or together with TNF-α. To induce oxidative stress, cells were treated with 10 µM tert-butylhydroperoxide (tBHP) for 20 h. To buffer intracellular Ca²⁺, MDA-MB231 cells were treated with 1 µM BAPTA-AM for 30 min. To induce high extracellular Ca²⁺ levels, we added 5 mM Ca²⁺ to the cell culture medium for 24 h. To induce endoplasmic reticulum (ER) stress, cells were treated with 1 µM thapsigargin (TG) for 24 h.

2.3. Quantitative real-time PCR

RNA was extracted using an RNeasy Mini Kit (QIA-GEN, Hilden, Germany) according to the manufacturer’s protocol. Briefly, cells were lysed and homogenized using QIAshredder spin columns (QIA-GEN) and RNA was bound to a RNeasy Mini Spin Column. To eliminate genomic DNA contamination, on-column DNA digestion was performed using RNase-Free DNase I in buffer RD (QIAGEN). After several washing steps, RNA was eluted. RNA concentration and quality were assessed with spectrophotometry (NanoDrop; Thermo Scientific, Waltham, MA, USA). Using a High-Capacity cDNA Reverse Transcription Kit (4368814; Thermo Fisher Scientific), 1 µg RNA was then reverse-transcribed to cDNA in a total reaction volume of 20 µL. Subsequently, the cDNA reaction was diluted with a dilution factor of 1 : 3. Real-time quantitative PCR was performed on MicroAmp Fast 96-well reaction plates (Applied Biosystems, Waltham, MA, USA) using 1 µL of the diluted cDNA reaction per well and Power SYBR Green PCR Master Mix (Applied Biosystems) in a 7300 Real-Time PCR System (Thermo Fisher Scientific). Data were analyzed using the ΔΔCₜ method (Livak and Schmittgen, 2001) and ribosomal protein 18S used as a housekeeping gene. The following primers were used at a concentration of 5 µM: NCS1 (forward, 5′-GATGCTGGACATTGTGGATG-3′; reverse, 5′-CTTGGAACCCCTCCTGGAAC-3′); 18S (forward, 5′-TTGTAACGCTGTCCCTATCAA-3′; reverse, 5′-ATGGTAGGCACGGCAGACTA-3′).

2.4. Western blot analysis

2.4.1. Whole-cell lysates

Cells were lysed in ice-cold mammalian protein extraction reagent (PER) buffer (Thermo Fisher Scientific) supplemented with a protease inhibitor, sodium fluoride, and sodium orthovanadate (Santa Cruz Biotechnology, Dallas, TX, USA).

2.4.2. Extraction of nuclear and cytosolic fractions

To obtain cytosolic and nuclear fractions, NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific) were used according to the manufacturer’s protocol. Cells were harvested with TrypLE, centrifuged, and washed in PBS. A reagent ratio of 200 cytoplasmic extraction reagent I (CER I): 11 cytoplasmic extraction reagent II (CER II): 100 nuclear extraction reagent (NER) was used. Ice-cold CER I containing protease inhibitor was added to the cell pellet and vortexed to fully suspend the cell pellet. The cell suspension was incubated for 10 min on ice. Ice-cold CER II was added, vortexed, and incubated for 1 min on ice. After an additional vortexing step and following centrifugation, the cytoplasmic extract was obtained from the supernatant. Ice-cold NER was added to the insoluble fraction (pellet) containing the nuclei. After several vortexing steps, the suspension was centrifuged and the nuclear protein fraction was obtained from the supernatant.

All protein concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). SDS/PAGE was performed with 10–30 µg protein. Protein was transferred to a polyvinylidene difluoride membrane (GE Healthcare, Arlington Heights, IL, USA), resulting blots were blocked for 1 h at room temperature (RT) in 5% nonfat dry milk or, for phosphorylated proteins, in 5% BSA in 1X Tris-buffered saline supplemented with Tween-20 (TBS-T), then incubated with primary antibody overnight at 4 °C. The following antibodies were used NCS1 (ab116230; Abcam, Cambridge, MA, USA;
diluted 1 : 2000), GAPDH (Cell Signaling Technology, Danvers, MA, USA, #2118; diluted 1 : 5000), Akt (Cell Signaling #9272; diluted 1 : 1000), phospho-Akt (Ser473; Cell Signaling #9271; diluted 1 : 1000), NFκB p65 (Abcam ab16502; diluted 1 : 2000), nuclear factor of kappa-light polypeptide gene enhancer in B-cell inhibition, alpha (IκBα; Abcam ab7217; diluted 1 : 500), Lamin (Abcam ab8984; diluted 1 : 500). Following primary antibody incubation, membranes were washed with 1X TBS-T and incubated with a horseradish peroxidase-labeled goat IgG (Santa Cruz Biotechnology) at RT for 2 h. Membranes were washed, incubated in Pierce ECL western blotting solution (Thermo Fisher Scientific) and developed on X-ray film in a dark room.

2.5. TRANSFAC database analysis

The TRANSFAC database (Matys et al., 2006) was used to identify potential transcription factor binding sites in the predicted human NCS1 promoter region. After obtaining a list of transcription factors that potentially bind 200 kb upstream to 200 kb downstream of the predicted transcriptional start site (TSS) of NCS1, we reviewed the literature on their involvement in Ca²⁺ signaling or cancer progression.

2.6. Assessment of TNF signaling via NFκB and NCS1 expression in breast cancer RNA microarray dataset

RNA microarray analysis was performed on normal human breast (n = 5) and human breast tumor (n = 8) tissue as described previously (Harvell et al., 2013). Data were obtained from the Gene Expression Omnibus (GSE31192) and analyzed using QuTore Omics Explorer (Lund, Sweden). Gene expression values were log₂-transformed and fold change calculated. A curated list of genes associated with TNF signaling via NFκB (BioCarta Gene Set M5890) was collected from Gene Set Enrichment Analysis Gene Sets (Broad Institute) and used to generate an expression heat map of differentially regulated (P < 0.05) NFκB-regulated genes in normal versus cancerous breast tissue. Gene expression values of NCS1 mRNA were plotted in normal versus cancerous breast tissue and against expression values of the catalytic subunit of protein phosphatase 2A (PP2Ac).

2.7. Alteration of NCS1 levels in MDA-MB231 cells

To study the cellular effect of high NCS1 expression, MDA-MB231 cells were stably transfected with a vector encoding for human NCS1 or a control vector as described previously (Moore et al., 2017). Breast cancer cells lacking NCS1 expression (NCS1 KO) were generated through CRISPR/Cas9 gene editing. The CRISPR/Cas9 vector used, pSpCas9(BB)-2A-GFP (PX458), was a gift from Feng Zhang (Addgene plasmid #48138, Watertown, MA, USA) (Ran et al., 2013). Control cells (WT) were transfected with a PX458 vector containing a scrambled gRNA sequence. To generate NCS1 KO cells, the CRISPR/Cas9 vector was modified to contain gRNA targeting NCS1. For this purpose, the following gRNA pair was designed: forward, 5’-CACCCTTGAAGCCCGAAGTTGTGG-3’ reverse, 5’-AAACCCACAACCTCCGCGCTCAAC-3’. After annealing these two nucleotide sequences, the gRNA was inserted in the PX458 vector backbone. The construct was transformed into DH5α bacteria, selected with ampicillin, and isolated using a QIAprep Spin Miniprep Kit (QIAGEN) according to the manufacturer’s protocol. The insert was validated by sequencing. Quality and concentration of the DNA were validated with spectrophotometry (NanoDrop; Thermo Scientific). For transfection of MDA-MB231 cells, MDA-MB231 cells were plated on 100-cm dishes 24 h prior to transfection. Afterward, cells were transfected for 48 h with either the NCS1-PX458 vector or the scrambled PX458 vector control. Transfection was performed using FuGene HD transfection reagent (Promega, Madison, WI, USA) according to the manufacturer’s protocol. As the PX458 vector contains GFP, FACS cell sorting was performed to isolate successfully transfected cells by selecting single GFP-positive cells into 96-well plates. These cells were grown in complete growth medium until the wells were confluent. Colonies were tested for successful NCS1 KO by western blot analysis and IF. The primary antibody for NCS1 was obtained from Abcam (ab116230) and was used in 1 : 2000 dilution for western blotting and 1 : 500 for IF.

2.8. Fluorescence microscopy

For fluorescence microscopy, MDA-MB231 WT and NCS1 KO cells were seeded on sterile glass coverslips and grown to 80% confluency. Medium was removed, and each coverslip was washed twice with 2 mL of 1× PBS (pH 7.4; American Bio, Natick, MA, USA). Fixation was performed for 15 mi at RT with 4% paraformaldehyde. After several washes in 1× PBS supplemented with 0.1% Tween-20 (PBS-T), cells were permeabilized in 0.1% Triton X-100 for 5 min. Following permeabilization, cells were washed and blocked for 1 h at RT in 1X PBS-T supplemented with
10% normal goat serum (Cell Signaling Technology Inc.). Cells were incubated at 4 °C overnight with a rabbit anti–NCS1 monoclonal antibody (ab116230; Abcam; diluted 1 : 500) diluted in blocking solution. After washing with PBS, cells were incubated with AlexaFluor-488 goat anti-rabbit secondary antibody (1 : 1000 dilution; Thermo Fisher Scientific) and rhodamine-conjugated phalloidin (1 : 1000 dilution; Thermo Fisher Scientific) for 2 h at RT in the dark. Cells were washed with PBS and mounted on glass slides with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific). Slides were cured overnight before images were captured with a confocal microscope (LSM 710 Duo; Carl Zeiss, Oberkochen, Germany).

2.9. Proliferation assay
Cell proliferation was assessed using a luminescent-based assay that measures the number of viable cells in culture based on ATP levels (CellTiter-Glo Luminescence Cell Viability Assay [Promega]). One thousand cells were seeded into each well of a sterile 96-well plate except for the wells at the edges of the plate. The relative number of viable cells was measured from day 0 to 4 by adding 100 μL of CellTiter-Glo Reagent (Promega) to 10 wells per timepoint and genotype. The cells were incubated in this reagent for 15 min at RT to stabilize the luminescent signal. Luminescence was measured on a microplate reader (Tecan Infinite M1000 Pro; Tecan Trading, Mannedorf, Switzerland). Three independent experiments were performed using MDA-MB231 WT and NCS1 KO cells with 10 wells per timepoint and genotype.

2.10. Scratch motility assay
Scratch motility assays were performed by growing MDA-MB231 WT and NCS1 KO cells to confluency in six-well plates. After cells were serum-starved (1% FBS) for 12 h, a T-shaped wound was induced in the cell layer using a sterile pipette tip. Cells were washed with sterile PBS to remove detached cells. Wound width was assessed at timepoints of 0 and 24 h by capturing images of the scratch under a light microscope. Wound widths at different locations of the wound were measured using ImageJ software and the mean for each wound was calculated. The difference between the width at 0 and 24 h was calculated and depicted as mean wound closure in cm in 24 h. Four independent experiments were performed in triplicate for each genotype.

2.11. Colony formation assay
To study cell survival, we performed colony formation assays on MDA-MB231 WT and NCS1 KO cells. MDA-MB231 WT or NCS1 KO cells were seeded on 12-well plates at an initial number of 100 or 500 cells. Cells were counted using a hemacytometer and incubated for 10 days in complete growth medium at 37 °C and 5% CO2. After 10 days, cells were fixed with 100% ice-cold methanol and colonies were stained with 2.5% crystal violet. Plates were scanned with a conventional scanner and the area covered by cell colonies was analyzed with ImageJ (Guzmán et al., 2014). Data were obtained from 4 independent experiments with four replicates in each experiment and expressed as area covered with colonies in %.

2.12. Calcium imaging
Fluorescence-based Ca2+ imaging was performed using a fluorescence microscope (Orca 2 camera imaging system [Metamorph] mounted on a Zeiss inverted microscope). To measure the response to UTP, the Ca2+ reporter dye Fluo-4-AM (Thermo Fisher Scientific) was used. Baseline Ca2+ and response to TG were measured using the ratiometric dye Fura-2-AM (Thermo Fisher Scientific). Ca2+ responses to UTP and TG were measured in Ca2+-free conditions to abolish effects of extracellular Ca2+ on the measured response. Baseline Ca2+ was assessed in Ca2+-containing conditions. Ca2+-containing HEPES-buffered saline (HBS) contained 1.25 mM CaCl2, 19.7 mM HEPES, 4.7 mM KCl, 1.2 mM KH2PO4, 1 mM MgSO4, 130 mM NaCl, and 5 mM dextrose in dH2O, pH 7.4 at RT. In Ca2+-free HBS buffer CaCl2 was replaced by 1.25 mM MgCl2 and additionally 0.1 mM EGTA was added. MDA-MB231 WT or NCS1 KO cells were plated on glass coverslips 1 day prior to imaging at a density of 100 000 cells per coverslip. After 1 day of growth, cells were incubated at 37 °C in 5% CO2 for 40 min with Fura-2-AM or Fluo-4-AM dissolved in Ca2+-containing HBS buffer with 0.03% pluronic acid (Thermo Fisher Scientific). Excess dye was washed away with Ca2+-containing HBS buffer. Cells were incubated for another 10 min in Ca2+-containing HBS. To measure the effect of the intracellular Ca2+ chelator BAPTA-AM on baseline Ca2+ levels, WT and NCS1 KO cells were incubated with Fura-2-AM supplemented with 1 μM BAPTA-AM prior to imaging. Once in view on the fluorescence microscope, approximately 20 single cells plus one empty area (background) were identified and defined as regions of interest. For Ca2+ responses to UTP and TG, cells were perfused with Ca2+-free
HBS for 30 s before imaging was started. After 10 s of imaging (F0), cells were stimulated with 10 µM UTP or 5 µM TG in Ca²⁺-free HBS. After 30 s of stimulation with UTP or 60 s stimulation with TG, cells were perfused with Ca²⁺-free HBS until the fluorescence signal returned to baseline. For baseline Ca²⁺ measurements, the ratiometric fluorescence signal of unstimulated cells in Ca²⁺-containing HBS buffer was recorded over 100 s. To investigate the Ca²⁺ response to stimulation with UTP measured with Fluo-4-AM, data were analyzed by subtracting the background from all measured values followed by normalization of each timepoint to the average of the first 10 s (F1/F0). Maximal amplitude, area under the curve (AUC), and rate of rise were calculated using GRAPHPAD PRISM Maximal amplitude, area under the curve (AUC), and rate of rise were calculated using GRAPHPAD PRISM 7 (San Diego, CA, USA). Baseline Ca²⁺ measurements with Fura-2-AM were analyzed by calculating the mean ratio of fluorescence at 340 and 380 nm under unstimulated conditions in Ca²⁺-containing HBS buffer. The response to TG measured with Fura-2-AM was analyzed by normalizing the 340/380 ratio of each timepoint to the mean 340/380 ratio at baseline.

2.13. Statistical analysis

Unless otherwise specified, each experiment was performed at least three times. Depicted are bar graphs including individual data points showing mean ± SD or box plots showing the median, interquartile range, and whiskers ranging from the minimum to maximum value. Experiments were blinded for treatments and genotypes where applicable. Statistical analyses were performed using GRAPHPAD PRISM 7. Gaussian distribution of datasets was checked with Shapiro–Wilk normality test before applying parametric statistical tests. Significance between two groups was assessed with unpaired Student’s t-tests if the data passed normality test. For comparison of groups of three or more, ordinary one-way ANOVA followed by Tukey post hoc test was performed. In cases of failed normality test, we applied nonparametric Mann–Whitney U-test. *P values < 0.05, **P < 0.01, ***P < 0.001.

3. Results

3.1. NCS1 is up-regulated in response to NFκB-activating stressors

To identify stimuli that lead to altered NCS1 expression, we investigated transcription factors predicted to regulate NCS1 gene transcription. For this purpose, we analyzed the predicted promoter region of NCS1 to identify potential transcription factor binding sites using TRANSFAC, a database encompassing information on eukaryotic transcription factors, their genomic binding sites, and DNA binding profiles (Matys et al., 2006). Our analysis revealed a binding site for the NFκB subunit RelA-p65 within the predicted NCS1 promoter, 88 to 99 kilobases downstream of the predicted NCS1 TSS (Fig. 1A). TNF-α is a well-established activator of the transcription factor and regulator of cellular stress, NFκB (Balkwill, 2009; Ben-Neriah and Karin, 2011; Oliveira-Marques et al., 2007; Pahl, 1999). TNF-α binds to TNF receptors 1 and 2 to activate the IkB kinase complex, leading to the degradation of IkB and consequent nuclear translocation of NFκB. In the nucleus, NFκB binds to specific DNA binding motifs to regulate the expression of a variety of different genes (Pahl, 1999; Tian et al., 2005). To test whether NCS1 is regulated by NFκB, we treated SHSY5Y human neuroblastoma cells with TNF-α and consequently measured NCS1 protein expression. NCS1 protein abundance increased in SHSY5Y cells treated with TNF-α for 24 h (Fig. 1B, C). NFκB activation after TNF-α treatment was confirmed by immunoblotting for IkBα in whole-cell lysate and for NFκB in cytosolic and nuclear cell fractions. Treatment with TNF-α for 24 h resulted in IkBα degradation (Fig. 1B, D) and translocation of NFκB to the nucleus (Fig. 1E), confirming NFκB activation. Measuring NCS1 mRNA expression showed increased mRNA levels of NCS1 following treatment with TNF-α (Fig. 1F), suggesting that NCS1 up-regulation happens on a transcriptional level. To induce NFκB signaling through an additional stressor, we treated SHSY5Y cells for 20 h with tBHP, which was also reported to activate NFκB (Pahl, 1999). Measurements of NCS1 mRNA expression again showed an increase of NCS1 following treatment with tBHP (Fig. 1G). Other conditions, namely high extracellular Ca²⁺ or TG, did not change NCS1 expression (Fig. S1). These results suggest that NCS1 is transcriptionally up-regulated by extracellular stressors that specifically activate NFκB.

3.2. TNF-α-induced NCS1 up-regulation is NFκB-dependent

To conclusively determine whether TNF-α-induced NCS1 up-regulation is caused by NFκB activation, we examined the effect of pharmacological NFκB inhibition on NCS1 expression using the NFκB inhibitor Bay 11-7082 (Bay). This compound inhibits the degradation of IkBα, therefore preventing nuclear...
translocation of NFκB. After treating SHSY5Y cells with Bay for 24 h and immunoblotting for IκBα, we saw that IκBα protein levels increased (Fig. 2A,B), demonstrating the successful inhibition of IκBα degradation and hence NFκB activation. Treatment with the NFκB inhibitor alone caused a slight but not significant decrease of NCS1 protein levels (Fig. 2A,C), but did significantly decrease NCS1 mRNA expression (Fig. 2D). These data suggest that NFκB regulates transcription of NCS1, but NCS1 protein has a longer half-life than our treatment time of 24 h. We hypothesize that longer treatment with Bay would show diminished levels of NCS1 protein. Cotreatment of cells with TNF-α and Bay abrogated the TNF-α-induced NCS1 increase (Fig. 2E), confirming that TNF-α induces NCS1 expression through a NFκB-dependent mechanism.

3.3. NCS1 up-regulation corresponds with NFκB activation in human breast cancer

To investigate the relevance of TNF signaling via NFκB activation and NCS1 up-regulation in human cancer, we analyzed the gene expression patterns of NFκB-regulated genes and NCS1 expression in a dataset from an RNA microarray performed on human breast cancer and noncancerous breast tissue. A heat map of NFκB-regulated genes was generated from RNA expression values of noncancerous (normal) and cancerous (tumor) breast cancer. We found that genes transcriptionally regulated by NFκB have a distinct expression pattern in breast cancer tissue compared to normal breast tissue, indicating the differential regulation of NFκB signaling in breast cancer (Fig. 3A). Furthermore, we found that NCS1
Fig. 2. TNF-α-induced NCS1 up-regulation is NFκB-dependent. (A) Western blot analysis of SHSY5Y whole-cell lysates treated with DMSO (CTRL) or 1 µM of the NFκB inhibitor Bay 11-7082 (Bay) for 24 h. Depicted is a representative blot. Bay treatment significantly increased IkBα compared to CTRL as quantified in (B). Depicted is the mean ± SD of n = 3 independent experiments, *P < 0.05, determined by unpaired Student’s t-test. (C) 24 h of NFκB inhibition caused a slight, but not significant decrease of NCS1 protein. Depicted is the mean ± SD of n = 3 independent experiments, *P > 0.05, determined by unpaired Student’s t-test. (D) Quantitative real-time PCR of SHSY5Y cells treated with DMSO (CTRL) or 1 µM Bay for 24 h. NCS1 mRNA expression decreased with NFκB inhibition compared to CTRL. Depicted are box plots of n = 4 independent experiments. **P < 0.01, determined by unpaired Student’s t-test. (E) Quantitative real-time PCR of SHSY5Y treated with DMSO (CTRL), 10 ng·µL⁻¹ TNF-α, or 10 ng·µL⁻¹ TNF-α + 1 µM Bay for 24 h. TNF-α-induced increase of NCS1 mRNA (**P < 0.01) was prevented by cotreatment with Bay (*P < 0.05). Depicted are box plots of n = 4 independent experiments. Statistical significance was determined by ordinary one-way ANOVA followed by Tukey post hoc test.

Fig. 3. NCS1 and NFκB-regulated genes are differentially expressed in human breast cancer tissue compared to normal breast tissue. (A) Expression heat map of differentially expressed (P < 0.05) NFκB-regulated genes in normal (n = 5) versus cancerous breast tissue (n = 8). NFκB-related genes show distinct expression patterns between groups, indicating altered NFκB-signaling in human breast cancer. A color legend is pictured with a scale from −2 to +2-fold change. (B) Gene expression values of NCS1 mRNA were plotted in normal (n = 5) versus cancerous breast tissue (n = 8) and revealed increased NCS1 gene expression in human breast cancer compared to normal breast tissue. **P < 0.01, determined by Student’s t-test. RNA microarray analysis was performed as described previously (Harvell et al., 2013). Data were obtained from the Gene Expression Omnibus (GSE31192).
expression was significantly higher in breast cancer samples compared to normal breast samples (Fig. 3B). These findings give relevance to the results from our in vitro experiments, as they show that NCS1 up-regulation corresponds with NFκB activation in human breast cancer pathophysiology. In addition, these results further support our hypothesis that NCS1-dependent signaling has a specific function in breast cancer.

### 3.4. CRISPR/Cas9 knockout of NCS1

Having determined that NFκB signaling and NCS1 are altered in human breast cancer, we moved to investigate the specific role of NCS1 in breast cancer. To this end, we generated MDA-MB231 cells lacking NCS1 using CRISPR/Cas9 technology. MDA-MB231 NCS1 KO and control (WT) cells were confirmed through immunofluorescence (IF) staining (Fig. 4A) and western blot analysis (Fig. 4B).

### 3.5. NCS1 KO renders cells deficient in colony formation and migration capabilities

Whereas previous publications focused on the effect of NCS1 overexpression (NCS1 OE) on promoting tumor aggressiveness (Apasu et al., 2019; Moore et al., 2017), here we investigate the effect of NCS1 KO on cell survival, migration, and proliferation. Colony formation assays in MDA-MB231 WT and NCS1 KO cells were used to study cell survival. Assays were performed with 100 or 500 cells seeded in six-well cell culture dishes and cells were allowed to grow undisturbed for 10 days. After fixing and staining the resulting colonies, the percentage of culture dish area covered by colonies was calculated. NCS1 KO formed significantly fewer colonies compared to WT cells (Fig. 5A, B) suggesting poorer cell survival. We then measured the effect of NCS1 on cell migration by performing wound healing assays on WT and NCS1 KO cells. After a standardized wound was induced in WT and NCS1 KO cells growing in culture, wound closure was quantified by measuring the distance that cells moved in 24 h. NCS1 KO moved significantly less compared to WT (Fig. 5C, Fig. S2A–D), demonstrating defective migration and survival capabilities in these cells. Cell proliferation was then assessed using a luminescence-based assay that measures the number of viable cells based on the level of ATP present, but no significant difference in proliferation was seen between WT and NCS1 KO cells (Fig. 5D), consistent with previous findings (Moore et al., 2017; Wang et al., 2016). These results demonstrate an important role for NCS1 in cell survival and migration, but not cell proliferation.

### 3.6. NCS1 knockout reduces InsP3-dependent ER Ca²⁺ release and increases baseline cytosolic Ca²⁺ levels, which can be rescued by intracellular Ca²⁺ chelation

Neuronal calcium sensor 1 is an established Ca²⁺-binding protein (Burgoyne, 2007), and it is known that NCS1 increases InsP3R activity at the single channel.

---

**Fig. 4.** Generation of NCS1 KO MDA-MB231 cells. (A) Representative IF images of WT and NCS1 KO MDA-MB231 cells stained for NCS1 (green), phalloidin (red), and DAPI (blue). The large panels show merged images of all three channels and the small panels show the different channels separately. (B) Western blot of WT and NCS1 KO MDA-MB231 cells, confirming successful deletion of NCS1 protein expression in KO cells.
level (Schlecker et al., 2006). Because the InsP3R is known to regulate cancer progression (Akl and Bultynck, 2013), we aimed to determine how NCS1 affects cellular Ca\(^{2+}\) homeostasis and signaling in breast cancer cells. For this purpose, we performed fluorescence imaging of intracellular Ca\(^{2+}\) in WT and NCS1 KO MDA-MB231 cells to investigate NCS1-dependent regulation of InsP3-dependent ER Ca\(^{2+}\) release and baseline intracellular Ca\(^{2+}\) levels. The effect of NCS1 on InsP3-dependent Ca\(^{2+}\) responses in WT and NCS1 KO cells was monitored using fluorescence imaging of Ca\(^{2+}\) transients in live cells stimulated with UTP. UTP is an agonist of the purinergic P2Y receptor, causing phosphoinositide phospholipase C-mediated InsP3 generation and consequent Ca\(^{2+}\) release from the ER through the InsP3R (Erb and Weisman, 2012). Imaging revealed that the amplitude of the Ca\(^{2+}\) response was decreased in NCS1 KO compared to WT cells (Fig. 6A,B), and quantification of the AUC showed that the total amount of Ca\(^{2+}\) released was significantly less in NCS1 KO cells (Fig. 6C). Additionally, the Ca\(^{2+}\) transient rate of rise in NCS1 KO cells was significantly smaller than in WT cells (Fig. 6D). To rule out the possibility that the decreased Ca\(^{2+}\) response in NCS1 KO cells was due to decreased steady-state ER Ca\(^{2+}\) content, we investigated the Ca\(^{2+}\) response to TG, a drug that induces ER Ca\(^{2+}\) depletion via inhibition of sarco/ER Ca\(^{2+}\)-ATPase. Stimulation of WT and NCS1 KO cells with 5 \(\mu\)M TG did not reveal any difference of the ER Ca\(^{2+}\) content between the two genotypes (Fig. 6E,F). To focus on Ca\(^{2+}\) responses from internal stores, the experiments with UTP and TG were performed in Ca\(^{2+}\)-free HBS. At baseline, we found a significantly higher fluorescence signal in NCS1 KO cells compared to WT cells, indicating increased resting Ca\(^{2+}\) levels with NCS1 KO. The increased baseline intracellular Ca\(^{2+}\) levels could be rescued by treatment of NCS1 KO cells with the
intracellular Ca\(^{2+}\) chelator, BAPTA-AM (Fig. 6G). These results show that upon InsP3-generating stimuli, NCS1 enhances ER Ca\(^{2+}\) release independent of ER Ca\(^{2+}\) content and that under resting conditions, NCS1 is crucial for maintaining low intracellular Ca\(^{2+}\) levels through its function as a Ca\(^{2+}\) buffer.

### 3.7. NCS1 increases Akt activity

Akt, also known as protein kinase B (PKB), is a well-established survival-promoting protein (Song et al., 2005) that also promotes cell migration and other cancer-related processes (Chin and Toker, 2009; Xue and Hemmings, 2013). Akt has been linked to NCS1 signaling, as cardiomyocytes lacking NCS1 expression have less stress-induced activation of the Akt pathway (Nakamura et al., 2016). Here, we used MDA-MB231 cells to investigate the effect of NCS1 on baseline Akt activity, comparing cells with WT, KO, and OE levels of NCS1 (Fig S3). Akt is activated through PI3K and phosphatidylinositol (3,4,5)-trisphosphate, leading to phosphorylation and consequent activation of Akt at
Threonine308 (T308) and Serine473 (S473). As phosphorylation at S473 indicates full Akt activation (Sarbassov et al., 2005), we examined Akt activity through immunoblotting for Akt phosphorylation at S473 (p-Akt (S473)). Western blot analysis of MDA-MB231 WT, NCS1 KO, and NCS1 OE cells revealed decreased basal Akt activity in NCS1 KO compared to WT cells (Fig. 7A). Conversely, NCS1 OE cells showed increased basal Akt activity (Fig. 7B). Because NCS1 KO cells had increased baseline Ca²⁺ levels which could be rescued with the chelation of intracellular Ca²⁺, we investigated the effect of BAPTA-AM on Akt activity (Fig. 7C–E). Buffering intracellular Ca²⁺ with BAPTA-AM led to a significant increase of p-Akt levels in NCS1 KO cells (Fig. 7C), whereas no effect could be observed in WT and NCS1 OE cells (Fig. 7D,E). These data suggest that increased baseline Ca²⁺ in NCS1 KO cells causes decreased basal Akt activity and that NCS1 buffering of intracellular Ca²⁺ is crucial for maintaining proper Akt signaling.
4. Discussion

In this study, we (a) establish the Ca\(^{2+}\)-binding protein NCS1 as a stress response protein that is up-regulated by NF\(\kappa\)B-activating stimuli, (b) reinforce its importance for cell survival and motility, and (c) demonstrate that NCS1 modulates Ca\(^{2+}\) signaling and Akt activity, both of which are important for cancer progression (Monteith et al., 2017; Vivanco and Sawyers, 2002) (Fig. 8). A key finding of this study is that NCS1 is transcriptionally up-regulated in response to cellular stress through the activation of NF\(\kappa\)B. NF\(\kappa\)B is a central regulator of the cellular stress response (Mercurio and Manning, 1999) and can be activated by a broad range of stimuli (Pahl, 1999). Cancer cells are embedded in a very complex microenvironment that consists of a variety of such environmental stressors, including TNF-\(\alpha\) (Cairns et al., 2011; Landskron et al., 2014; Salvatore et al., 2017). NF\(\kappa\)B is an established regulator of several pro-survival and pro-migratory genes (Baud and Karin, 2009; Ben-Neriah and Karin, 2011; Hoesel and Schmid, 2013; Karin et al., 2002; Taniguchi and Karin, 2018), and many types of cancer have been linked to constitutive NF\(\kappa\)B activation (Baud and Karin, 2009; Karin et al., 2002; Pires et al., 2017; Piva et al., 2006). We showed that treatment of SHSY5Y cells with the pro-inflammatory cytokine TNF-\(\alpha\) activates the transcription factor NF\(\kappa\)B and increases NCS1 expression. Cotreatment with TNF-\(\alpha\) and an NF\(\kappa\)B inhibitor prevented the up-regulation of NCS1, indicating that TNF-\(\alpha\)-induced up-regulation of NCS1 is NF\(\kappa\)B-dependent. The oxidative stressor tBHP is also known to activate NF\(\kappa\)B (Pahl, 1999) and led to up-regulation of NCS1 as well. Additionally, analysis of the NCS1 promoter region using TRANSFAC predicted a binding site for the NF\(\kappa\)B subunit RelA-p65 within the predicted promoter region of NCS1, further supporting our hypothesis that NCS1 is transcriptionally up-regulated through NF\(\kappa\)B-activating signals. We demonstrated the relevance of these in vitro findings for human breast cancer through analysis of human RNA expression data, which showed the activation of NF\(\kappa\)B signaling in breast cancer tissue in concordance with NCS1 up-regulation. These findings indicate that up-regulation of NCS1 via NF\(\kappa\)B is relevant in human breast cancer pathophysiology. Although previous studies showed that high NCS1 expression leads to more aggressive behavior of tumor cells, specifically increased cell survival and motility and worse patient outcome (Aparasu et al., 2019; Moore et al., 2017; Schuette et al., 2018), our observations are a first step toward understanding how high NCS1 levels become elevated in cancer cells. Our results raise the possibility that targeting the NF\(\kappa\)B-activating tumor microenvironment could prevent up-regulation of NCS1 and other stress response proteins that consequently lead to a more aggressive tumor phenotype.

With the evidence that there is a specific mechanism of NCS1 up-regulation with stress, the question arises regarding the specific function of NCS1 in cancer cells, and which cellular signaling pathways are regulated by NCS1 to promote tumor aggressiveness. In the present study, we further validate the importance of NCS1 for cell survival and motility and provide evidence that NCS1 modulates signaling pathways important for cancer progression. Through the use of NCS1 KO cells, we showed opposite responses when compared to previous studies with NCS1 OE (Aparasu et al., 2019; Moore et al., 2017). Specifically, NCS1 KO led to decreased cell survival and motility compared to WT cells. Our data indicate that NCS1 affects cell survival and motility through the modulation of Ca\(^{2+}\) signaling and consequent regulation of Akt activation. We found that NCS1 regulates Ca\(^{2+}\) homeostasis and signaling by maintaining low intracellular Ca\(^{2+}\) levels under resting conditions and by enhancing InsP3-dependent ER Ca\(^{2+}\) release. Additionally, we found that NCS1 increases Akt signaling in a Ca\(^{2+}\)-dependent manner.

**Fig. 8.** NCS1 as stress response protein: proposed mechanism. Environmental stressors such as TNF-\(\alpha\) or oxidative stress, which activate the transcription factor NF\(\kappa\)B, lead to transcriptional up-regulation of NCS1. NCS1 functions as cytosolic Ca\(^{2+}\) buffer, increases InsP3-dependent ER Ca\(^{2+}\) release, and activates the Akt pathway. Increased NCS1 expression therefore causes disrupted Ca\(^{2+}\) signaling and increased Akt activity and consequently promotes cell survival and motility.
manner. Both Ca\textsuperscript{2+} signaling and Akt are well-established modulators of cell survival and motility (Monteith et al., 2017; Vivanco and Sawyers, 2002). We found that under resting conditions, NCS1 KO cells have higher intracellular Ca\textsuperscript{2+} levels than WT cells, and that this increase can be rescued by the intracellular Ca\textsuperscript{2+} chelator BAPTA-AM, indicating that NCS1 is crucial for maintaining low resting Ca\textsuperscript{2+} concentrations, which may be explained through two mechanisms. First, it is possible that NCS1 acts as a Ca\textsuperscript{2+} buffer. Typically, Ca\textsuperscript{2+} buffers have low Ca\textsuperscript{2+}-binding affinity, are highly abundant in the cytosol, chelate Ca\textsuperscript{2+}, and often terminate Ca\textsuperscript{2+} signals upon binding of Ca\textsuperscript{2+} (Schwaller, 2010). Second, it is also possible that NCS1 acts as a Ca\textsuperscript{2+}-sensor protein. Ca\textsuperscript{2+}-sensor proteins have a high affinity to Ca\textsuperscript{2+} and, upon binding of Ca\textsuperscript{2+}, change their confirmation and interact with effector proteins (Burgoyne, 2007). Because NCS1 is a high-affinity, low-capacity Ca\textsuperscript{2+}-binding protein (Burgoyne, 2007), it is likely that NCS1 maintains low resting Ca\textsuperscript{2+} conditions through its interactions with other associated effector proteins, rather than acting as a Ca\textsuperscript{2+} buffer. Additionally, we demonstrated that under resting conditions, the survival- and migration-promoting Akt pathway (Song et al., 2005; Wang et al., 2012; Xue and Hemmings, 2013) is less active in NCS1 KO compared to WT cells and shows enhanced activity in NCS1 OE cells. Buffering intracellular Ca\textsuperscript{2+} with BAPTA-AM increases Akt activity in NCS1 KO cells but not in WT or NCS1 OE cells. These results indicate that the increased resting Ca\textsuperscript{2+} levels in NCS1 KO cells lead to decreased Akt activity. We cannot completely rule out the possibility that BAPTA-AM affects Akt activity through another mechanism than buffering Ca\textsuperscript{2+}. However, as BAPTA-AM is widely used as a Ca\textsuperscript{2+} chelator and we were able to validate its Ca\textsuperscript{2+}-buffering function in our cells, it is most likely that Akt activity is increased due to Ca\textsuperscript{2+} buffering. Consistent with our findings, a previous study showed that prolonged high intracellular Ca\textsuperscript{2+} increases the expression of the endogenous Akt inhibitor PP2Ac, leading to less Akt activity. Conversely, Ca\textsuperscript{2+} buffering with BAPTA-AM decreases PP2Ac expression and increases Akt activity (Yasuoka et al., 2004). Analysis of the RNA expression data from human noncancerous and breast cancer tissue revealed a negative correlation between NCS1 expression and PP2Ac expression (Fig. S4A), supporting the hypothesis that low NCS1 levels lead to higher Ca\textsuperscript{2+} levels, consequently increasing PP2Ac expression and less Akt activity. However, we could not confirm this correlation through immunoblotting for PP2Ac (Fig. S4B). Most likely, western blot was not sensitive enough to detect a difference between the two genotypes. Because of this, we cannot conclusively claim that enhanced PP2Ac expression is the reason for decreased Akt activity in NCS1 KO cells. It does remain an intriguing possibility, however, and will require further studies to elucidate this mechanism more thoroughly. It should be noted that the literature surrounding the effect of intracellular Ca\textsuperscript{2+} on Akt activity remains controversial. There are studies supporting our results, showing that high intracellular Ca\textsuperscript{2+} levels decrease Akt phosphorylation and that buffering intracellular Ca\textsuperscript{2+} can increase Akt phosphorylation (Conus et al., 1998; Kang et al., 2017). Conversely, other studies claim that increased intracellular Ca\textsuperscript{2+} promotes Akt activity (Divolis et al., 2016; Wang et al., 2017). Certainly, there are underlying mechanisms in the regulation of Akt that remain incompletely understood and that require further studies in the future. In our hands, we conclude that increased intracellular resting Ca\textsuperscript{2+} levels can explain the observed decrease in Akt activity in NCS1 KO cells, which also explains these cells’ decreased cell survival and motility.

Besides the effect of resting Ca\textsuperscript{2+} on cancer-related pathways, dysregulated Ca\textsuperscript{2+} release from internal stores such as the ER can influence cancer development and progression (Monteith et al., 2017). We observed a diminished Ca\textsuperscript{2+} response to the InsP\textsubscript{3}-generating external stimulus UTP in MDA-MB231 NCS1 KO cells, indicating reduced Ca\textsuperscript{2+} release from the ER in the absence of NCS1. Another study reported that NCS1 silencing in MDA-MB231 cells has no major effect on ER Ca\textsuperscript{2+} signaling (Bong et al., 2019). However, the difference between our results can be attributed to differences in the experimental setup. Specifically, the previous study used a model of transient NCS1 silencing, which incompletely deleted NCS1 expression which would markedly reduce the ability to detect NCS1-dependent effects on Ca\textsuperscript{2+} signaling. Our study used cell lines with stable KO and OE of NCS1. In addition, the previous study used high concentrations of the protease trypsin and ATP to induce InsP\textsubscript{3}-mediated ER Ca\textsuperscript{2+} release, whereas this study used UTP, an agonist optimized for this cell line, to tease out differences among genotypes. Furthermore, Ca\textsuperscript{2+} transients in the previous study were recorded using a plate reader, which has well-documented limitations and is less sensitive compared to single cell-based Ca\textsuperscript{2+} imaging (Heusinkveld and Westerink, 2011). By using an optimized experimental setup to study the effects of long-term NCS1 deletion on Ca\textsuperscript{2+} signaling, using UTP as an agonist to induce InsP\textsubscript{3}-mediated Ca\textsuperscript{2+} release, and utilizing single cell-based Ca\textsuperscript{2+} imaging, our data identify NCS1 as an
important regulator of the InsP3-mediated Ca\(^{2+}\) response.

We suggest that the findings in our study have implications on tumor aggressiveness. Previously, it was shown that NCS1 preferentially localizes to the leading edge of migrating cells (Apasu et al., 2019), which have a rear-to-front Ca\(^{2+}\) gradient with high levels of Ca\(^{2+}\) at the rear and lower Ca\(^{2+}\) at the leading edge. Disrupted Ca\(^{2+}\) homeostasis can therefore lead to abnormal migration of cancer cells (Tsai et al., 2015; Wei et al., 2009). Because NCS1 keeps Ca\(^{2+}\) concentrations low under resting conditions and upon stimulus enhances ER Ca\(^{2+}\) release, we suggest that NCS1 facilitates cell movement by regulating Ca\(^{2+}\) signals at the leading edge.

5. Conclusion

Overall, our study is the first to elucidate an underlying signaling mechanism through which the Ca\(^{2+}\)-binding protein NCS1 influences tumor aggressiveness and progression (Fig. 8). We identified NCS1 as a stress response protein that is up-regulated by exogenous stressors that activate the transcription factor NFkB, a central regulator of the cell stress response. We found that this mechanism of NCS1 up-regulation is conserved in the pathophysiology of human breast cancer, and we showed that NCS1 has essential functions for cell survival and migration through altering intracellular Ca\(^{2+}\) signaling and Akt signaling. The novel finding that extracellular stressors lead to NCS1 up-regulation helps us understand how high NCS1 expression leads to more aggressive behavior of tumor cells and worse patient outcome (Apasu et al., 2019; Moore et al., 2017; Schuette et al., 2018). In conclusion, we describe a novel role for NCS1 as stress response protein linking the tumor microenvironment and cancer progression. As NCS1 is ubiquitously expressed, our findings raise the possibility that NCS1 also contributes to other disease states that are related to the activation of the cellular stress response through NFkB and Ca\(^{2+}\) signaling.

Acknowledgements

The authors thank Lien Nguyen and Fernanda Lemos (Yale University School of Medicine, New Haven, CT, 06510) for helpful discussions regarding study design, experimental procedures, and editorial support.

Data accessibility

All specialized reagents generated for this study are available by contacting the corresponding author.

Conflict of interest

HKG, TTF, and JAS received a scholarship from the German Academic Scholarship Foundation. NIH support is acknowledged: GM007324, 5P01DK057751 (BEE), and F31DK118836 (ALB) supported this work. We acknowledge the use of the Yale Center for Cellular and Molecular Imaging (NIH grants 5P30DK034989 and OD020142). BEE is a founder of Osmol Therapeutics, a company that is targeting NCS1 for therapeutic purposes. The other authors declare no conflicts of interest.

Author contributions

HKG and BEE designed the study. HKG performed the majority of the experiments, analyzed the results, and drafted the manuscript. TTF, ALB, and JAS performed additional experiments. HKG, TTF, ALB, and BEE edited the manuscript. All authors edited and agreed to the final version of the manuscript.

References

Akl H and Bultynck G (2013) Altered Ca\(^{2+}\) signaling in cancer cells: proto-oncogenes and tumor suppressors targeting IP3 receptors. Biochem Biophys Acta 1835, 180–193.

Apasu JE, Schuette D, LaRanger R, Steinle JA, Nguyen LD, Grosshans HK, Zhang M, Cai WL, Yan Q, Robert ME et al. (2019) Neuronal calcium sensor 1 (NCS1) promotes motility and metastatic spread of breast cancer cells in vitro and in vivo. FASEB J 33, 4802–4813.

Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9, 361–371.

Baud V and Karin M (2009) Is NF-\(\kappa\)B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33–40.

Ben-Neriah Y and Karin M (2011) Inflammation meets cancer, with NF-\(\kappa\)B as the matchmaker. Nat Immunol 12, 715–723.

Boeckel GR and Ehrlich BE (2018) NCS-1 is a regulator of calcium signaling in health and disease. Mol Cell Res Bioch Biophys Acta 1865, 1660–1667.

Bong AHL, Robitaille M, Milevskiy MJG, Roberts-Thomson SJ and Monteith GR (2019) NCS-1 expression is higher in basal breast cancers and regulates calcium influx and cytotoxic responses to doxorubicin. Mol Oncol 14, 87–104.

Bourne Y, Dannenberg J, Pollmann V, Marchot P and Pongs O (2001) Immunocytochemical localization and crystal structure of human frequenin (neuronal calcium sensor 1). J Biol Chem 276, 11949–11955.
Bresnick AR, Weber DJ and Zimmer DB (2015) S100 proteins in cancer. *Nat Rev Cancer* **15**, 96–109.

Burgoyne RD (2007) Neuronal calcium sensor proteins: generating diversity in neuronal Ca²⁺ signalling. *Nat Rev Neurosci* **8**, 182–193.

Cairns RA, Harris IS and Mak TW (2011) Regulation of cancer cell metabolism. *Nat Rev Cancer* **11**, 85–95.

Carafoli E (2002) Calcium signaling: a tale for all seasons. *Proc Natl Acad Sci USA* **99**, 1115–1122.

Chin YR and Toker A (2009) Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. *Cell Signal* **21**, 470–476.

Clapham DE (2007) Calcium signaling. *Cell* **131**, 1047–1058.

Conus NM, Hemmings BA and Pearson RB (1998) Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k. *J Biol Chem* **273**, 4776–4782.

de Oliveira-Marques V, Cyrne L, Marinho HS and Antunes F (2007) A quantitative study of NF-kappaB activation by H₂O₂: relevance in inflammation and synergy with TNF-alpha. *J Immunol (Baltimore, Md.)* **150**, 3893–3902.

Divolis G, Mavroedi P, Mavrofrydi O and Papazafiri P (2016) Differential effects of calcium on PI3K-Akt and HIF-1α survival pathways. *Cell Biol Toxicol* **32**, 437–449.

Donato R, Cannon BR, Sorci G, Ruzzi F, Hsu K, Weber DJ and Geczy CL (2013) Functions of S100 proteins. *Curr Mol Med* **13**, 24–57.

Dragicevic E, Poetschke C, Duda J, Schlauraff F, Lammel S, Schiemann J, Fauler M, Hetzel A, Watanabe M, Lujan R et al. (2014) Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. *Brain* **137**, 2287–2302.

Erb L and Weisman GA (2012) Coupling of P2Y receptors to G proteins and other signaling pathways. *Wiley Interdiscip Rev Membr Transp Signal* **1**, 789–803.

Graham TR and Burd CG (2011) Coordination of Golgi functions by phosphatidylinositol 4-kinases. *Trends Cell Biol* **21**, 113–121.

Guzmán C, Bagga M, Kaur A, Westermarck J and Abankwa D (2014) ColonyArea: An ImageJ plugin to automatically quantify colony formation in clonogenic assays. *PLoS ONE* **9**, e92444.

Harvell DME, Kim J, O’Brien J, Tan A-C, Borges VF, Schedin P, Jacobsen BM and Horwitz KB (2013) Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. *Horm Cancer* **4**, 140–153.

Heusinkveld HJ and Westerink R (2011) Caveats and limitations of plate reader-based high-throughput kinetic measurements of intracellular calcium levels. *Toxicol Appl Pharmacol* **255**, 1–8.

Hoesel B and Schmid JA (2013) The complexity of NF-κB signaling in inflammation and cancer. *Mol Cancer* **12**, 86.

Joo JH, Kim JW, Lee Y, Yoon SY, Kim JH, Paik S-G and Choe IS (2003) Involvement of NF-kappaB in the regulation of S100A6 gene expression in human hepatoblastoma cell line HepG2. *Biochem Biophys Res Commun* **307**, 274–280.

Kang JK, Kim O-H, Hur J, Yu SH, Lamichhane S, Lee JW, Ojha U, Hong JH, Lee CS, Cha J-Y et al. (2017). Increased intracellular Ca²⁺ concentrations prevent membrane localization of PH domains through the formation of Ca²⁺-phosphoinositides. *Proc Natl Acad Sci USA* **114**, 11926–11931.

Karin M, Cao Y, Greten FR and Li Z-W (2002) NF-κB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer* **2**, 301–310.

Koizumi S, Rosa P, Willars GB, Challiss RAI, Taverna E, Francolini M, Bootman MD, Lipp P, Inoue K, Roder J et al. (2002) Mechanisms underlying the neuronal calcium sensor-1-evoked enhancement of exocytosis in PC12 cells. *J Biol Chem* **277**, 30315–30324.

Landskron G, de La Fuente M, Thuwajit P, Thuwajit C and Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. *J Immunol Res* **2014**, 149185.

Li Z, Tang M, Ling B, Liu S, Zheng Y, Nie C, Yuan Z, Zhou L, Guo G, Tong A et al. (2014) Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. *J Mol Med (Berlin, Germany)* **92**, 291–303.

Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods (San Diego, CA)* **25**, 402–408.

Mutys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barré-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K et al. (2006) TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. *Nucleic Acids Res* **34**, D108–D110.

Mercurio F and Manning AM (1999) NF-kappaB as a primary regulator of the stress response. *Oncogene* **18**, 6163–6171.

Monteith GR, Prevorskaya N and Roberts-Thomson SJ (2017) The calcium–cancer signalling nexus. *Nat Rev Cancer* **17**, 373–380.

Moore LM, England A, Ehrlich BE and Rimm DL (2017) Calcium sensor, NCS-1, promotes tumor aggressiveness and predicts patient survival. *Mol Cancer Res* **15**, 942–952.

Moore LM, Wilkinson R, Altan M, Toki M, Carvajal-Hausdorf DE, McGuire J, Ehrlich BE and Rimm DL (2018) An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients. *NPJ Breast Cancer* **4**, 6.
Nakamura TY, Jeromin A, Mikshiba K and Wakabayashi S (2011) Neuronal calcium sensor-1 promotes immature heart function and hypertrophy by enhancing Ca\textsuperscript{2+} signals. Circ Res 109, 512–523.

Nakamura TY, Jeromin A, Smith G, Kurushima H, Koga H, Nakabeppu Y, Wakabayashi S and NabeKura J (2006) Novel role of neuronal Ca\textsuperscript{2+} sensor-1 as a survival factor up-regulated in injured neurons. J Cell Biol 172, 1081–1091.

Nakamura TY, Nakao S and Wakabayashi S (2016) Neuronal Ca\textsuperscript{2+} sensor-1 contributes to stress tolerance in cardiomyocytes via activation of mitochondrial detoxification pathways. J Mol Cell Cardiol 99, 23–34.

Nakamura-Nishitani TY and Wakabayashi S (2014) Role of neuronal calcium sensor-1 as a regulator of immature heart function and cardiac hypertrophy. Ped Cardiol Card Surg 30, 224–231.

Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6835–6866.

Pires BR, Mencalhu AL, Ferreira GM, de Souza WF, Morgado-Diaz JA, Maia AM, Correa S and Abdelhay ESFW (2017) NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS ONE 12, e0169622.

Piva R, Belardo G and Santoro MG (2006) NF-kappaB: a stress-regulated switch for cell survival. Antioxid Redox Signal 8, 478–486.

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA and Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281–2308.

Salama I, Malone PS, Miahimeed F and Jones JL (2008) A review of the S100 proteins in cancer. Eur J Surg Oncol 34, 357–364.

Salvatore V, Teti G, Focaroli S, Mazzotti MC, Mazzotti A and Falcioni M (2017) The tumor microenvironment promotes cancer progression and cell migration. Oncotarget 8, 9608–9616.

Sarbassov DD, Guertin DA, Ali SM and Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (New York, N.Y.) 307, 1098–1101.

Schaad NC, de Castro E, Nef S, Hegi S, Hinrichsen R, Martone ME, Ellisman MH, Sikkink R, Rusnak F, Sygush J et al. (1996). Direct modulation of calmodulin targets by the neuronal calcium sensor NCS-1. Proc Natl Acad Sci USA 93, 9253–9258.

Schlecker C, Boehmerle W, Jeromin A, DeGray B, Varshney A, Sharma Y, Szidgeti-Buck K and Ehrlich BE (2006) Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium. J Clin Investig 116, 1668–1674.

Schuette D, Moore LM, Robert ME, Taddei TH and Ehrlich BE (2018) Hepatocellular carcinoma outcome is predicted by expression of neuronal calcium sensor 1. Cancer Epidemiol Biomarkers Prev 27, 1091–1100.

Schwaller B (2010) Cytosolic Ca\textsuperscript{2+} buffers. Cold Spring Harbor Perspect Biol 2, a004051.

Sippy T, Cruz-Martín A, Jeromin A and Schweizer FE (2003) Acute changes in short-term plasticity at synapses with elevated levels of neuronal calcium sensor-1. Nat Neurosci 6, 1031–1038.

Song G, Ouyang G and Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9, 59–71.

Taniguchi K and Karin M (2018) NF-kB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18, 309–324.

Tian B, Nowak DE, Jamaluddin M, Wang S and Brasier AR (2005) Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 280, 17435–17448.

Tsi-F-C, Kuo G-H, Chang S-W and Tsi-P-J (2015) Ca\textsuperscript{2+} signaling in cytoskeletal reorganization, cell migration, and cancer metastasis. Biomed Res Int 2015, 409245.

Vivanco I and Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489–501.

Wang B, Boeckel GR, Huynh L, Nguyen L, Cao W, de La Cruz EM, Kaftan EJ and Ehrlich BE (2016) Neuronal calcium sensor 1 has two variants with distinct calcium binding characteristics. PLoS ONE 11, e0161414.

Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, White M, Reichelt J and Levine B (2012) Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science (New York, N.Y.) 338, 956–959.

Wang Y, He J, Zhang S and Yang Q (2017) Intracellular calcium promotes radioresistance of non-small cell lung cancer A549 cells through activating Akt signaling. Tumour Biol 39, 1–7.

Wei C, Wang X, Chen M, Ouyang K, Song L-S and Cheng H (2009) Calcium flickers steer cell migration. Nature 457, 901–905.

Weiss J, Hui H and Bourgoine RD (2010) Neuronal calcium sensor-1 regulation of calcium channels, secretion, and neuronal outgrowth. Cell Mol Neurobiol 30, 1283–1292.

Xue G and Hemmings BA (2013) PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 105, 393–404.

Yasuoka C, Ibara Y, Ikeda S, Miyahara Y, Kondo T and Kohno S (2004) Antiapoptotic activity of Akt is down-regulated by Ca\textsuperscript{2+} in myocardial H9c2 cells. Evidence of Ca\textsuperscript{2+}-dependent regulation of protein phosphatase 2A. J Biol Chem 279, 51182–51192.
Zhao X, Várnai P, Tuymetova G, Balla A, Tóth ZE, Oker-Blom C, Roder J, Jeromin A and Balla T (2001) Interaction of neuronal calcium sensor-1 (NCS-1) with phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and affects membrane trafficking in COS-7 cells. *J Biol Chem* **276**, 40183–40189.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig S1.** NCS1 mRNA expression does not change with all cell stressors.
**Fig S2.** Wound healing assay.
**Fig S3.** MDA-MB231 cells stably overexpressing NCS1.
**Fig S4.** Effect of NCS1 expression on endogenous Akt inhibitor PP2Ac.
Fig S1-S4